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Background and Objective: Oral anticoagulation (OAC) for secondary stroke
prevention is recommended in atrial fibrillation (AF) and other sources of cardioembolic
stroke. Our objectives were to explore the differences in ischemic and hemorrhagic
events when using OAC for secondary stroke prevention according to the type of
anticoagulant treatment and to analyze the number and reasons for OAC switches during
long-term follow-up.
Methods: Ischemic stroke (IS) patients who were discharged on OAC for secondary
stroke prevention from January 2014 to October 2017 were recruited in a prospective,
multicenter, hospital-based registry. Follow-up at 3 months was scheduled at the
outpatient clinic with subsequent annual phone interviews for 3 years. Patients were
classified into three study groups according to OAC at discharge: Vitamin K antagonist
(VKA), Factor Xa inhibitor (FXa), or direct thrombin inhibitor (DTI). We compared stroke
recurrences, intracranial hemorrhage, major bleeding, and all-cause mortality during the
follow-up. We recorded any switches in OAC and the main reasons for the change.
Results: A total of 241 patients were included. An anticoagulant was indicated in the
presence of a source of cardioembolic stroke in 240 patients (99.6%) and lupus plus
antiphospholipid syndrome in one patient. Up to 86 patients (35.6%) were on OAC before
the index stroke; in 71 (82.5%) of them, this was VKA. At hospital discharge, 105 were
treated with FXa (43.8%), 96 with VKA (39.6%), and 40 with DTI (16.6%). The cumulative
incidences at 3 years were 17% for stroke recurrence, 1.6% for intracranial hemorrhage,
4.9% for major hemorrhage, and 22.8% for all-causemortality, with no differences among
the OAC groups in any outcomes. During the follow-up, 40 OAC switches were recorded
(63% of them to FXa), mostly due to stroke recurrence.
Gutiérrez-Zúñiga et al. The Prospective Multicentre Restaic Registry
Conclusion: Long-term OAC in secondary stroke prevention is associated with a lower
frequency of bleeding complications than stroke recurrences. No differences between
anticoagulant drugs were found in any of the analyzed outcomes. The main cause for
OAC switch during follow-up was stroke recurrence.
Keywords: secondary stroke prevention, anticoagulant drugs, stroke recurrence, hemorrhage risk, multicenter
registry
INTRODUCTION
Current guidelines recommend oral anticoagulation (OAC)
for secondary stroke prevention in atrial fibrillation (AF)
and other sources of cardioembolic stroke (1, 2). Vitamin K
antagonists (VKA) were the only treatments available until the
publication of several clinical trials showing the non-inferiority
of direct oral anticoagulants (DOACs) in the prevention of
stroke and peripheral embolisms in patients with non-valvular
AF, with the advantage of lower risk of intracranial bleeding
complications (3). Therefore, since then, the prescription of
DOACs has increased for primary stroke prevention, with a
parallel decrease in VKA use (4, 5). Several real-life registries
found that DOACs are safe and effective drugs for primary
stroke prevention in AF patients (6–9). Moreover, evidence
supporting the efficacy and safety of DOACs comes from
randomized clinical trials that recruited AF patients at high
risk of stroke but with only about 19–52% of patients with
previous stroke or transient ischemic attack (TIA) (10–13).
All these trials have published the results of this subgroup of
patients showing consistently beneficial results in secondary
stroke prevention (14–17). Taking into account that stroke
patients are at high risk both of ischemic and hemorrhagic
strokes, and prevention of both are the main objectives in
this specific population, it seems necessary to monitor the
effects of OAC in non-selected patients in clinical practice.
Several registries have been published in recent years to
study the use of the various oral anticoagulant treatments in
stroke patients (18–26), mainly evaluating clinical outcomes
such as stroke recurrence, cerebral hemorrhage, or functional
outcome. Other published registries were focused on the use
of radiological markers such as cerebral microbleeds or white
matter hyperintensities in order to stratify the hemorrhagic risk
in this specific population (27, 28). Also, individual patient data
analysis of seven prospective cohort studies has been recently
published addressing the outcomes in patients with AF who
received anticoagulation treatment in secondary prevention after
stroke (29).
However, the “real-world” long-term outcomes of stroke
patients receiving OAC for any indication (not restricted to AF)
in secondary stroke prevention and the number and reasons for
OAC switches during follow-up are not well-known, missing
relevant information for the clinician.
Our aims were to evaluate the effects of OAC in long-
term outcomes in a secondary prevention clinical setting and




The RESTAIC (acronym corresponding to the Spanish
name REgistro clínico para el Seguimiento de Tratamiento
Anticoagulante en prevención secundaria tras un Infarto Cerebral;
Clinical registry for the follow-up of anticoagulant treatment
in secondary prevention following cerebral infarction) was a
multicenter, prospective, observational study supported by the
IdiPAZ research foundation, conducted in six departments
of neurology in Madrid, Spain (see the participant list in the
Acknowledgments section). Ischemic stroke (IS) patients who
were discharged on OAC were recruited from January 2014 to
October 2017. The prescription of OAC was the decision of
the treating physician. The study protocol did not provide a
recommendation for the prescription of one anticoagulant drug
over other.
The inclusion criteria were 18 years old or older (no upper
age limit), admitted with IS (TIA or cerebral infarction) with
indication of anticoagulation for secondary stroke prevention
(source of cardioembolic stroke or another indication), and able
to understand and sign the informed consent (in the event of
a patient’s incapacity, informed consent could be signed by a
relative). The exclusion criteria were participation in another
observational study or in clinical trials, severe disease with life
expectancy of<3 years, and patients who were not discharged on
OAC. The follow-up period after inclusion was up to 3 years. The
first assessment was during the hospital admission for the index
stroke, and the follow-up visits were scheduled as follows: one
visit at 3 months at the outpatient clinic and subsequent annual
telephone interviews for 3 years. These consultations were carried
out centrally from the main study center.
The study was approved by the ethics committee of each
participating hospital. The study was approved by the Spanish
Agency of Medicines and Medical Devices (Agencia Española de
Medicamentos y Productos Sanitarios).
Outcomes
The primary outcomes were ischemic stroke recurrence,
intracranial hemorrhage, major bleeding [defined according to
the International Society on Thrombosis and Haemostasis
(ISTH)] (30), and all-cause mortality. The secondary
outcomes were clinically relevant non-major bleeding
(CRNMB), defined according to the ISTH criteria (31):
minor bleeding, peripheral embolism, and vascular-related
mortality (ischemic stroke, intracranial hemorrhage, acute
myocardial infarction, acute heart failure, arrhythmia,
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and pulmonary thromboembolism). We also recorded
any switches in OAC during follow-up and the main
reasons for the change (stroke recurrence, intracranial
hemorrhage, major bleeding, CRNMB or minor bleeding,
peripheral embolism, labile INR in those treated with
VKA, and other reasons not related to direct complications
of anticoagulation).
Data Collection
A specific electronic case report form was developed
for this study on enrollment: demographic variables
(age, sex, educational level, and current occupational
activity); previous history of hypertension, diabetes
mellitus (DM), tobacco smoking, previous IS (other
than index stroke), or TIA, the presence of a source
FIGURE 1 | Flow chart of study enrollment.
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of cardioembolic stroke (AF, prosthetic valve, other
sources of cardioembolic stroke: other non-prosthetic
valvulopathy, intracardiac thrombus, ventricular akinesia,
left ventricular aneurysm, left ventricular ejection fraction
≤35%, patent foramen ovale, atrial septal aneurysm, dilated
cardiomyopathy, chronic heart failure, endocarditis, and
atrial myxoma). OAC prior to index stroke, Charlson
comorbidity index (CCI) (32), modified Rankin Scale
(mRS), CHA2-DS2-VASc and HAS-BLED scores at discharge
were recorded.
Additional variables relating to the index stroke were
recorded: main indication of OAC (source of cardioembolic
stroke or another noncardiac indication for anticoagulation) and
type of anticoagulant at discharge: Vitamin K antagonists
(VKA), Factor Xa inhibitors (FXa), or direct thrombin
inhibitors (DTI). At the follow-up visits, occurrences
of any primary or secondary outcomes were recorded.
Statistical Analysis
The statistical analysis was performed using SPSS 26.0 for
Windows (SPSS Inc., Chicago, IL). First, we carried out a
descriptive analysis of the total cohort. Categorical variables
were presented as proportions and continuous variables as the
mean and standard deviation (SD) or median and interquartile
range (IQR).
TABLE 1 | Demographic characteristics of the total cohort.












Sex male, n (%) 132 (54.8) 59 (61.5) 53 (50.5) 20 (50) 0.23
Age; years, mean (±SD) 74.1 (11.8) 70.2 (12.5) 77.8¶ (10.2) 73.4(10.9) <0.001
Educational level, n (%)
Unable to read or write 15 (6.2) 10 (10.4) 4 (3.8) 1 (2.5) 0.20
Read and write only 40 (16.5) 11 (11.5) 21 (19.8) 8 (20)
Primary/secondary education 110 (45.4) 47 (49) 49 (46.7) 18 (45)
Higher non-university studies 24 (9.9) 14 (14.6) 8 (7.6) 2 (5)
University/college degree 49 (20.2) 14 (14.6) 23 (22.6) 11 (27.5)
Occupational activity, n (%)
Not working 40 (16.5) 14 (14.6) 21 (20) 5 (12.5) 0.08
Working 34 (14) 21 (21.9) 6 (5.7) 7 (17.5)
Incapacity 9 (3.7) 6 (6.3) 2 (2) 1 (2.5)
Retired 159 (65.7) 55 (57.3) 76 (72.4) 27 (67.5)
Hypertension, n (%) 189 (78.4) 67 (69.8) 91 (86.7) ¶ 31 (77.5) 0.01
Diabetes mellitus, n (%) 61 (25.3) 18 (18.8) 31 (29.5) 12 (30) 0.16
Dyslipidemia, n (%) 148 (61.4) 60 (62.5) 65 (61.9) 23 (57.5) 0.85
Chronic kidney disease, n (%) 17 (7.1) 7 (7.3) 8 (7.6) 2 (5) 0.87
Tobacco smoking, n (%) n (%) 35 (14.5) 18 (18.8) 12 (11.4) 5 (12.5) 0.31
Previous TIA or IS, n (%) 63 (26.1) 17 (17.7)¶ 32 (30.5) 14 (35) 0.04
Previous peripheral embolism, n (%) 5 (2.1) 2 (2.1) 2 (1.9) 1 (2.5) 0.97
Previous source of cardioembolic stroke, n (%)
AF 171 (70.7) 44 (45.8)¶ 92 (86.8) 35 (87.5) <0.001
Prosthetic valve 14 (5.8) 14 (14.6) 0 0
Others 27 (11.2) 26 (27.1) 1 (0.9) 0 -
Previous anticoagulant, n (%)
VKA 71 (29.5) 24 (25) 36 (34.3) 11 (27.5) 0.22
FXa 12 (5) 0 8 (7.6) 4 (10) -
DTI 3 (1.2) 0 2 (1.9) 1 (2.5) -
Main indication for anticoagulation at discharge, n (%)
AF 188 (78) 44 (45.8)¶ 104 (99) 40 (100) <0.001
Prosthetic valve 14 (5.8) 14 (14.6) 0 0 -
Other source of cardioembolic stroke 38 (15.8) 38 (39.6) 1 (1) 0 -
Other non-cardiac conditions 1 (0.4) 0 0 -
CCI at discharge; median (IQR) 1 (0–2) 2 (0–3) 1 (0–2) 1(0–2) 0.36
mRS at discharge; median (IQR) 1 (0–2) 1 (0–2) 1 (0–3) 1 (0–3) 0.03
CHA2-DS2-VASc at discharge; median (IQR) 5 (4–6) 5¶ (3–6) 6¶ (5–7) 5 (4–7) <0.001
HAS-BLED at discharge; median (IQR) 2 (2–3) 2¶ (2–3) 3¶ (2–3) 2 (2–3) <0.01
*Comparative analysis of the 3 anticoagulant groups: VKA, FXa and DTI.
¶Statistically significant differences after Bonferroni correction. CCI, Charlson Comorbidity Index; IS, Ischaemic stroke; TIA, Transient ischaemic attack; AF, Atrial fibrillation; VKA, Vitamin
K antagonist; FXa, Factor Xa inhibitor; DTI, Direct thrombin inhibitor.
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Baseline and demographic characteristics were then analyzed
and compared among the various types of anticoagulants at
discharge: VKA, FXa, and DTI. Categorical variables were
compared using X2 or Fisher’s exact test where appropriate, and
quantitative variables were compared using ANOVA test and
underwent post hoc adjustment using the Bonferroni test. We
performed an intention-to-treat analysis.
We calculated the cumulative incidence for the primary
and secondary outcomes at 3-years follow-up, and those
were compared using a Kaplan–Meier and log rank
analysis, according to the anticoagulant type at discharge
(VKA vs. FXa vs. DTI). Moreover, we performed a
multivariate Cox regression analysis by the “enter” method,
adjusting by sex, age, Charlson comorbidity index, and
previous stroke.
Finally, a descriptive analysis of switches among anticoagulant
drugs and main reasons for them during the 3-years follow-
up was carried out. All tests were two-tailed; significance was
assumed when p < 0.05
RESULTS
A total of 241 patients were enrolled, but 52 patients dropped out
of the study during follow-up: two patients refused to continue
with the telephone interviews, and 50 patients could not be
FIGURE 2 | Type of anticoagulant treatment at the time of index stroke, at hospital discharge, and at 3 years of follow-up. VKA, vitamin K antagonist; FXa, Factor Xa
inhibitor; DTI, direct thrombin inhibitor; pNone, no previous anticoagulant treatment; pVKA, previously treated with vitamin K antagonist; pFXa, previously treated with
Factor Xa inhibitor; pDTI, previously treated with direct thrombin inhibitor; 3yVKA, VKA at 3 years of follow-up; 3yFXa, Factor Xa inhibitor at 3 years of follow-up; 3yDTI,
direct thrombin inhibitor at 3 years of follow-up.
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contacted after several attempts (Figure 1). The study database
was closed in April 2020, after completion of a 3 years follow-up
in 189 patients. The mean time of follow-up was 31.2 months.
The total patient-years of follow up was 1,261.75 patients/year.
The patients who did not complete the entire follow-up were
younger (mean age 71.6 vs. 74.78 years) and had a lower
rate of dyslipidemia (48 vs. 65%), with no other differences in
demographics and baseline characteristics.
The demographics and baseline characteristics of the cohort
are described inTable 1. Two hundred forty patients had a source
of cardioembolic stroke as the main indication for OAC, and
only one patient had a non-cardioembolic disease (lupus plus
antiphospholipid syndrome). At hospital discharge, 105 patients
(43.6%) received FXa, 96 (39.8%) VKA, and 40 (16.6%) DTI
treatment. In general, patients given FXawere older, with a higher
proportion of hypertension and higher scores on the CHA2-DS2-
VASc and HAS-BLED scales. VKA-treated patients had a higher
proportion of non-AF sources of cardioembolic stroke as a main
reason for anticoagulation than the other groups.
For each participant, OAC before the index stroke and after
discharge is shown in Figure 2. Eighty-six patients (35.6% of the
total cohort) were on anticoagulation before the index stroke. Of
these, 71 (82.5%) were on VKA treatment. Noticeably, 61.1% of
the INR values were below the recommended range at admission
(according to specific indication: non-valvular AF or mechanical
prosthetic valve).
Another notable finding is that 63 patients (26% of the
total cohort) had already had a stroke before the index stroke.
Only 32 (50% of them) were on anticoagulation treatment
before the index stroke, the majority of them receiving VKA
(n = 23; 71.87%). Eighteen patients changed to DOAC, and
only five patients, previously VKA anticoagulated in secondary
stroke prevention, maintained VKA at discharge after the
index stroke—four of them because of the presence of a
contraindication to a DOAC (two patients with prosthetic valves,
one patient with valvular AF, and one patient with ventricular
akinesia). None of the patients previously treated with DOAC
changed to VKA for the index stroke.
The results for the primary and secondary outcomes are
shown in Table 2. Overall, we did not find any differences
in outcomes between the treatment groups. The cumulative
incidence at 3 years was 17% for stroke recurrence, 1.6% for
intracranial hemorrhage, 4.9% for major bleeding, and 22.8% for
all-cause mortality, with no differences between anticoagulant
groups in the Kaplan–Meier analysis (Figures 3, 4). Regarding
the baseline characteristics, patients with a previous stroke
presented higher stroke recurrence (22.2 vs. 9.5%, p = 0.01) and
overall mortality (33.3 vs. 19.1%, p= 0.021) after a 3-years follow-
up than patients without a previous history of stroke. The long-
term risk of stroke recurrence, intracranial hemorrhage, major
bleeding, and all-cause mortality was similar after adjustment for
age, sex, comorbidity, and previous stroke (Table 2).
Overall, there were no significant differences for the main
outcomes regarding the indication of anticoagulant therapy:
stroke recurrences (13.3 vs. 21.4% vs. 7.9%; p = 0.411),
intracranial hemorrhage (1.6% vs. 7.1% vs. 0%;p = 0.21), major
bleeding (4.3% vs. 14.3% vs. 5.3%; p = 0.25), and all-cause
TABLE 2 | Number of events, cumulative incidence, log-rank analysis, and hazard









FXa 20 0.94 (0.41–2.21)
DTI 4 0.68 (0.18–2.46)
Total 42 17% 1.07 0.58
INTRACRANIAL HEMORRHAGE
VKA 2 Ref.
FXa 1 0.43 (0.03–5.68)
DTI 1 1.45 (0.12–17.08)
Total 4 1.6% 61 0.73
MAJOR BLEEDING
VKA 6 Ref.
FXa 4 1.02 (0.06–15.53)
DTI 2 2.54 (0.17–37.17)
Total 12 4.9% 0.62 0.73
ALL-CAUSE MORTALITY
VKA 20 Ref.
FXa 25 0.44 (0.12–1.66)
DTI 10 0.83 (0.16–4.22)
Total 55 22% 0.43 0.78
CRNMH
VKA 15 Ref.
FXa 18 0.57 (0.15–2.02)
DTI 4 0.49 (0.08–2.78)
Total 35 14.4% 0.54 0.77
MINOR BLEEDING
VKA 17 Ref.
FXa 7 0.53 (0.13–2.16)
DTI 4 0.34 (0.04–2.97)
Total 28 11.6% 5.77 0.057
PERIPHERAL EMBOLISM
VKA 2 Ref.
FXa 2 0.37 (0.01–10.24)
DTI 2 0.55 (0.01–17.23)
Total 6 2.4% 1.36 0.50
VKA, vitamin K antagonist; FXa, Factor Xa inhibitor; DTI, direct thrombin inhibitor;
CRNNMH, clinically relevant nonmajor hemorrhage. Cox regression analysis adjusted by
sex, age, Charlson comorbidity index, and previous stroke.
mortality (21.3% vs. 21.4% vs. 31.6%; p= 0.38) for AF, prosthetic
valves, and minor cardioembolic sources, respectively.
For secondary outcomes, we found a trend to a higher
frequency ofminor bleeding with VKA treatment (17.7% vs. 6.6%
for FXa and 10% for DTI, p = 0.05). Among the 55 patients
deceased during the follow-up, only five had a vascular-related
cause of mortality; four of them were in the VKA group, and one
was in the FXa group. Similarly, there were no differences in the
long-term risk of secondary outcomes.
During the 3-years follow-up, none of the patients
discontinued the anticoagulation therapy, although 40 switches
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FIGURE 3 | Kaplan–Meier curve for stroke recurrence.
to another anticoagulant were made; 62% were changed to FXa,
24.4% to DTI, and only 13.3% to VKA. The main reasons for
changing were stroke recurrence (30%) and INR instability
(20%), followed by minor bleeding (17%) (Figure 5). None
of the patients changed the anticoagulant due to intracranial
hemorrhage; the two survivor patients who had intracranial
hemorrhage during follow-up were restored to the same DOAC
(FXa) for long-term anticoagulation.
The average last INR reported at each follow-up visit in the
VKA group was 2.6 (0.4 SD) at 3 months, 3.2 (1.1 SD) at 1
year, 1.5 (0.7 SD) at the second year, and 2.5 (0.7 SD) at the
third year.
DISCUSSION
In this prospective registry that reflected routine clinical practice
in secondary stroke prevention and included long-term follow-
up, we found a higher cumulative incidence of stroke recurrence
than of bleeding complications, without differences between
the different OACs prescribed. Some prospective registries have
analyzed the outcomes of patients on OAC in secondary stroke
prevention, and they showed similar results, with no differences
between VKA and DOACs regarding stroke recurrence (18, 33,
34). An individual patient data analysis of prospective studies
recently found that VKA was associated with higher rates
of mortality, intracranial hemorrhage, and combined vascular
events compared with DOACs, but again, the rates for stroke
recurrence were similar between groups (29).
Stroke patients represent a specific population in which the
risk of intracranial hemorrhage should be especially taken into
account (35, 36). In our study, we found a 17% cumulative
incidence for recurrent stroke at a 3-years follow-up, which is
comparable to other similar registries (17.5 and 18%) (4, 37). In
our cohort, only four intracranial hemorrhages (1.6% cumulative
incidence) were recorded at a 3-years follow-up, compared with
42 stroke recurrences. Similarly, in other registries, the rates
of stroke recurrence were higher than those of intracranial
hemorrhage (29, 38).
In our cohort, we did not find differences in the
anticoagulation treatments for intracranial hemorrhage, in
contrast to other registries that found a higher frequency of
intracranial hemorrhage and fatal intracranial hemorrhage with
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FIGURE 4 | Kaplan–Meier curve for mortality.
VKA (29, 39). The smaller sample size and the good baseline
functional status, with an average mRS of 1, of the patients
included could explain this result. Nevertheless, our results
also reinforce the idea of a higher risk of stroke recurrence
than intracranial hemorrhage in secondary stroke prevention at
long-term follow-up and, together with the MRI marker studies
(27, 28), could improve the clinician decision about long-term
anticoagulation in secondary prevention of stroke.
Patients with previous stroke before the index stroke
presented a significantly higher rate of stroke recurrence during
the follow-up. It is well-known that these patients are at higher
risk of ischemic events even if onOACs, and similar findings have
been previously reported (40). This should encourage us to look
for better strategies to improve secondary stroke prevention, such
as ensuring patients’ adherence to treatment. The NOACISP-
LONGTERM registry showed 78.4% of the patients to be
fully adherent with a median follow-up of 12 months, and a
recent systematic review showed that up to 30% of the patients
with AF are non-adherent to any OAC (22, 41). Likewise,
a Spanish study suggested that only 41.4% of the patients
are treated following the current Spanish recommendations in
clinical practice (42). In the Asian population, 18.8 and 13.1%
of patients are either undertreated or overtreated, respectively,
with a significant increase in adverse effects (43). Regarding the
type of anticoagulant used, almost 50% of the patients treated
with VKA are not well-anticoagulated, have diabetes, have labile
INR, and have a high HAS-BLED score being associated with
poor coagulation control (44). Although compliance is better
with DOACs than with VKA, it has been reported that 13% of
the AF patients receive DOAC doses that are inconsistent with
labeling (9.4% underdosed and 3.4% overdosed) (45). This may
reflect concerns about drug-related bleeding and may contribute
to a higher stroke recurrence rate. Therefore, usage of appropriate
dosage should be reinforced.
Frontiers in Neurology | www.frontiersin.org 8 October 2020 | Volume 11 | Article 575634
Gutiérrez-Zúñiga et al. The Prospective Multicentre Restaic Registry
Regarding secondary outcomes, we found no statistically
significant higher rates of minor bleeding with VKA treatment.
In fact, up to 17% of the patients reported switching the
anticoagulant drug due tominor bleeding. The concept of burden
due to anticoagulation treatment measured by the Anti-Clot
Treatment Scale (ACTS) (46) includes the perceived possibility
of bleeding as a result of vigorous and daily activities. Recent
studies found a strong association between patient dissatisfaction
with OAC treatment and increased stroke risk (47, 48), probably
due to lack of treatment adherence. In addition, another quality-
of-life registry showed that patients on DOACs experienced
higher satisfaction with oral anticoagulation than those on VKA
(49). In this sense, the 2019 AHA/ACC/HRS guidelines for
the management of patients with AF (50) recommend shared
decision making between clinicians and patients for better
adherence to treatment.
Another interesting finding in our study was the analysis of
the switches to another anticoagulant. Before the index stroke,
one third of the total cohort was on OAC, mostly VKA, and
about 61% of them had INR values below the recommended
range, consistent with other studies (21, 51). Therefore, in the
majority of patients previously treated with anticoagulants, the
index stroke was considered a therapeutic failure, and a change
to a DOAC was indicated. During the long-term follow-up,
the main reasons for a change of anticoagulant were stroke
recurrence and labile INR, the majority of switches being from
VKA to FXa. Current clinical guidelines recommend considering
changing to another OAC if the patient had a stroke while
already anticoagulated. However, the recommendation is weak
and based on expert opinion (52). While an INR test is easily
accessible for VKA, determination of DOAC activity is not
available in daily clinical practice. It would be interesting to
have a reliable test to anticipate the therapeutic failure and
then adapt a therapeutic strategy. In this regard a recent
study suggests that the activity of anticoagulation measured by
specific DOAC plasma levels on admission is associated with
stroke severity (53), and some studies support the reliability of
DOAC determination (54, 55) especially in patients with acute
ischemic stroke (56, 57). However, the ideal test is not yet widely
available, and more studies are needed to guide future treatment
decisions (58, 59).
The switch among anticoagulants could also reflect the
changes in recent years in anticoagulant drug prescriptions,
with the prescription of DOACs increasing in parallel with a
decline in the use of VKA. DOACs are associated with higher
adherence, easy use, fewer drug and food interactions, and lower
rates of all-cause mortality and bleeding events (4). Its simple
management without need of periodic ambulatory monitoring
has gained importance in current times during the COVID-19
pandemic, suggesting another advantage of DOAC treatment for
the future.
Our study has some limitations. First, the sample size was
small, and there was a clear selection bias because during
the inclusion period, recruiting centers participated in other
competing observational studies and clinical trials on acute
stroke and stroke prevention, a fact that could have limited the
FIGURE 5 | Reasons for anticoagulant switch during 3-years follow-up.
number of patients who were finally included in our registry;
the study protocol did not include a registry of the possible
candidates to participate in the study and the reason for the
exclusion. Second, most of the patients had a good functional
status at study entry, with a median mRS score of 1; therefore,
our results may not be able to be extrapolated to disabled stroke
patients. Third, we lack information on TTR for patients on
VKA, information that would be very valuable for a deeper
evaluation of the study outcomes and treatment adherence in
that group. Instead, in order to obtain an approximated value
of anticoagulation, we asked the participants to provide the
information on the last INR value at each follow-up visit. The
main strengths are the multicenter approach, the long-term
follow-up (most published studies were carried out with 1- or
2-years follow-up), and the evaluation of multiple variables not
usually included in the previously published registries (minor
bleedings and anticoagulant switching during the follow-up and
reasons for them).
CONCLUSION
In this prospective hospital-based cohort, the rates of
stroke recurrence in patients treated with anticoagulant
drugs in a secondary prevention setting were higher than
those of hemorrhagic complications, with no differences
between the anticoagulant drugs. The majority of the
changes between anticoagulants as a consequence of the
index stroke and during the follow-up were from VKA to
a DOAC, and the most common reason for change was
stroke recurrence.
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